Gilead Sciences, Inc.

You are here

Protocol GS-US-380-1961:

Protocol GS-US-380-1961: The study evaluates the efficacy of switching to an FDC of GS-9883/ F/TAF in virologically suppressed HIV-1 infected women as determined by the proportion of subjects with virologic failure at Week 48.


Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity

Gilead Protocol GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS9883 /Emtricitabine Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children